<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818440</url>
  </required_header>
  <id_info>
    <org_study_id>130092</org_study_id>
    <secondary_id>13-CC-0092</secondary_id>
    <nct_id>NCT01818440</nct_id>
  </id_info>
  <brief_title>Fluoroscopy or 3-D Roadmap Imaging Software for Liver Tumor Treatment</brief_title>
  <official_title>Prospective Randomized Trial Comparing Navigation With 3D Roadmap vs. Conventional Angiography During Transarterial Embolization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

      - Researchers are interested in comparing two methods that doctors can use to position
      catheters in blood vessels. These methods are used to deliver chemotherapy and close the
      blood supply to a tumor. The methods are the standard method called fluoroscopy and a new way
      called 3-D Roadmap. The 3-D Roadmap software uses computed tomography (CT) images to help the
      doctor choose the best position for the catheter to get to the tumor. The computer shows the
      route on an x-ray screen in real time. This technique may help doctors position the catheter
      with less x-ray dye and in a shorter time. These methods will be compared in people who are
      having a procedure to destroy liver tumors. The procedure, called trans-arterial
      embolization, will deliver chemotherapy and destroy the tumor blood supply.

      Objectives:

      - To compare the effectiveness of fluoroscopy or 3-D Roadmap software for liver tumor
      treatment.

      Eligibility:

      - Individuals at least 18 years of age who are having trans-arterial embolization for liver
      cancer.

      Design:

        -  Participants will be screened with a physical exam and medical history. They will
           provide blood and urine samples, and have imaging studies.

        -  Participants will be divided into two groups. One group will have regular fluoroscopy
           (X-ray) during the procedure. The other group will have the procedure with the 3-D
           Roadmap software.

        -  In the first group, participants will have a CT scan. The doctor will decide how many
           vessels need to be treated. The doctor will advance the catheter using fluoroscopy only.
           Another CT scan will be given after the procedure.

        -  In the second group, participants will have a CT scan. The doctor will look at the scan
           with the 3-D Roadmap software. The software will show the path to advance the catheter.
           The doctor will use the software to help destroy the tumors. Another CT scan will be
           given after the procedure.

        -  Both groups will have the same follow-up care afterward. Other tests will be given as
           needed for the cancer treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      This is a phase II prospective randomized trial comparing novel tumor segmentation and
      navigation with 3D roadmap vs. conventional imaging with angiography during trans-arterial
      embolization procedures. Cone beam CT (CBCT) obtains CT-like images in the angiography suite
      during trans-arterial chemoembolization procedures and liver chemo-perfusion (PHP). In
      addition, 2D liver perfusion metrics can be calculated from angiography images. 3D Roadmap is
      a navigation tool/ software that utilize the data from the CBCT overlaid on live fluoroscopy
      to display a segmented tumor, delineate its vascular supply and to navigate catheters to the
      target vessels. Moreover, with 3D Roadmap, CBCT can be fused to prior CT or MRI for improved
      target visualization. The 3D Roadmap software received 510 (k) clearance on February 19,
      2004. Our CRADA partner, Philips Healthcare, also submitted and received a separate 510 (k)
      clearance on January 30, 2015 for the software s vessel segmentation functionality and is
      under the trade name Emboguide. 3D Roadmap/ Emboguide software is intended to be used in
      combination with the AlluraClarity X-ray system.

      Primary Objective:

      To compare safety, and technical efficiency of navigation with 3D Roadmap vs. conventional
      image guidance during trans-arterial embolization procedures.

      Eligibility:

      Subjects are eligible if:

        -  They are more than 18 years of age

        -  They have primary or metastatic hepatic tumors scheduled for trans-arterial chemo-
           embolization or bland embolization in interventional radiology

        -  They are eligible for trans-arterial chemoembolization or bland embolization

      Subjects are excluded if they have:

        -  An altered mental status precluding understanding or consenting for the procedure

        -  Contra-indications to trans-arterial embolization

        -  A gross body weight exceeding 375 pounds (upper limit of angio table)

        -  A pregnancy

        -  A severe allergic reaction to iodine contrast which cannot be controlled by
           premedication with antihistamines and steroids

      Design:

        -  Number of Participants: 30

        -  Recruitment Time Frame: 2 years

        -  Number of sites: 1

        -  Type of Study: prospective randomized clinical trial
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 21, 2013</start_date>
  <completion_date type="Actual">September 16, 2015</completion_date>
  <primary_completion_date type="Actual">September 16, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare safety, efficacy, and technical efficiency of navigation with 3D Roadmap vs. conventional image guidance during trans-arterial embolization procedures.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Image-Guided Surgery</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will have the procedure performed using the 3-D Roadmap software.With the 3DRoadmap, images from a Cone-Beam CT are analyzed. Software shows the vessels supplying the tumor and the plan is displayed on top of fluoroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3D Roadmap software</intervention_name>
    <description>Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fluoroscopy</intervention_name>
    <description>Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

               1. Patients must have primary or metastatic hepatic tumors scheduled for
                  trans-arterial chemo-embolization or bland embolization in interventional
                  radiology. A multi-disciplinary team including oncology, surgery, pathology and
                  radiation oncology as well as interventional radiology will review each candidate
                  and determine the eligibility for TACE or bland embolization and ineligibility
                  for other interventions.

               2. Age &gt;18 years

               3. They must be eligible for trans-arterial chemoembolization or bland embolization

        EXCLUSION CRITERIA:

          1. Patients with an altered mental status precluding understanding or consenting for the
             procedure

          2. History of allergic reactions to iodine contrast, which cannot be controlled by
             premedication with antihistamines and steroids.

          3. Pregnant women are excluded from the study because ionizing radiation is teratogenic
             or abortifacient effects. Patients are excluded from pregnancy testing if they are
             above the childbearing age of 55 years old, or if they have documented history of
             infertility or acquired or congenital disorders incompatible with pregnancy or if the
             patient has had a hysterectomy or bilateral oophorectomy. Patients are also excluded
             from pregnancy testing if they are at least 50 years of age AND have not menstruated
             for at least 12 months OR have a documented Follicle Stimulating Hormone (FSH) level
             of greater than 40 mIU/mL.

          4. Patients with a total body weight exceeding 375 pounds since that is the weight limit
             of the angiography table.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradford J Wood, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health Clinical Center (CC)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-CC-0092.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Meyer BC, Witschel M, Frericks BB, Voges M, Hopfenm√ºller W, Wolf KJ, Wacker FK. The value of combined soft-tissue and vessel visualisation before transarterial chemoembolisation of the liver using C-arm computed tomography. Eur Radiol. 2009 Sep;19(9):2302-9. doi: 10.1007/s00330-009-1410-x. Epub 2009 May 8.</citation>
    <PMID>19424701</PMID>
  </reference>
  <reference>
    <citation>Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. Identification of pancreatic cancer stem cells. Cancer Res. 2007 Feb 1;67(3):1030-7.</citation>
    <PMID>17283135</PMID>
  </reference>
  <reference>
    <citation>Wallace MJ, Murthy R, Kamat PP, Moore T, Rao SH, Ensor J, Gupta S, Ahrar K, Madoff DC, McRae SE, Hicks ME. Impact of C-arm CT on hepatic arterial interventions for hepatic malignancies. J Vasc Interv Radiol. 2007 Dec;18(12):1500-7.</citation>
    <PMID>18057284</PMID>
  </reference>
  <verification_date>September 12, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical Navigation</keyword>
  <keyword>Liver</keyword>
  <keyword>Cancer</keyword>
  <keyword>Image-guided Therapy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

